[1]
Murinova N, Krashin D. Chronic daily headache. Physical medicine and rehabilitation clinics of North America. 2015 May:26(2):375-89. doi: 10.1016/j.pmr.2015.01.001. Epub 2015 Mar 6
[PubMed PMID: 25952071]
[2]
Sheeler RD, Garza I, Vargas BB, O'Neil AE. Chronic Daily Headache: Ten Steps for Primary Care Providers to Regain Control. Headache. 2016 Nov:56(10):1675-1684. doi: 10.1111/head.12881. Epub 2016 Aug 23
[PubMed PMID: 27552176]
[3]
Yancey JR, Sheridan R, Koren KG. Chronic daily headache: diagnosis and management. American family physician. 2014 Apr 15:89(8):642-8
[PubMed PMID: 24784123]
[4]
. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia : an international journal of headache. 2018 Jan:38(1):1-211. doi: 10.1177/0333102417738202. Epub
[PubMed PMID: 29368949]
[5]
Özge A, Faedda N, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalın OÖ, Lipton RB, Rapoport A, Guidetti V. Experts' opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents. The journal of headache and pain. 2017 Nov 23:18(1):109. doi: 10.1186/s10194-017-0818-y. Epub 2017 Nov 23
[PubMed PMID: 29285570]
Level 3 (low-level) evidence
[6]
Yamani N, Olesen J. New daily persistent headache: a systematic review on an enigmatic disorder. The journal of headache and pain. 2019 Jul 15:20(1):80. doi: 10.1186/s10194-019-1022-z. Epub 2019 Jul 15
[PubMed PMID: 31307396]
Level 1 (high-level) evidence
[7]
Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, Toom K, Vandervorst F, Quintana S, Paemeleire K, Katsarava Z. Medication-overuse headache: a widely recognized entity amidst ongoing debate. The journal of headache and pain. 2018 Jul 13:19(1):50. doi: 10.1186/s10194-018-0875-x. Epub 2018 Jul 13
[PubMed PMID: 30003412]
[8]
Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, Katsarava Z, Queiroz LP, Scher AI, Tekle-Haimanot R, Wang SJ, Steiner TJ. The methodology of population surveys of headache prevalence, burden and cost: principles and recommendations from the Global Campaign against Headache. The journal of headache and pain. 2014 Jan 27:15(1):5. doi: 10.1186/1129-2377-15-5. Epub 2014 Jan 27
[PubMed PMID: 24467862]
Level 3 (low-level) evidence
[9]
Probyn K, Bowers H, Caldwell F, Mistry D, Underwood M, Matharu M, Pincus T, CHESS Team. Prognostic factors for chronic headache: A systematic review. Neurology. 2017 Jul 18:89(3):291-301. doi: 10.1212/WNL.0000000000004112. Epub 2017 Jun 14
[PubMed PMID: 28615422]
Level 1 (high-level) evidence
[10]
Diener HC, Solbach K, Holle D, Gaul C. Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clinical medicine (London, England). 2015 Aug:15(4):344-50. doi: 10.7861/clinmedicine.15-4-344. Epub
[PubMed PMID: 26407383]
[11]
Wei DY, Khalil M, Goadsby PJ. Managing cluster headache. Practical neurology. 2019 Dec:19(6):521-528. doi: 10.1136/practneurol-2018-002124. Epub 2019 Jul 5
[PubMed PMID: 31278205]
[12]
Su M, Yu S. Chronic migraine: A process of dysmodulation and sensitization. Molecular pain. 2018 Jan-Dec:14():1744806918767697. doi: 10.1177/1744806918767697. Epub 2018 Apr 12
[PubMed PMID: 29642749]
[13]
Deen M, Christensen CE, Hougaard A, Hansen HD, Knudsen GM, Ashina M. Serotonergic mechanisms in the migraine brain - a systematic review. Cephalalgia : an international journal of headache. 2017 Mar:37(3):251-264. doi: 10.1177/0333102416640501. Epub 2016 Jul 11
[PubMed PMID: 27013238]
Level 1 (high-level) evidence
[14]
Deen M, Hansen HD, Hougaard A, Nørgaard M, Eiberg H, Lehel S, Ashina M, Knudsen GM. High brain serotonin levels in migraine between attacks: A 5-HT(4) receptor binding PET study. NeuroImage. Clinical. 2018:18():97-102. doi: 10.1016/j.nicl.2018.01.016. Epub 2018 Jan 28
[PubMed PMID: 29387527]
[15]
Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019 May:59(5):659-681. doi: 10.1111/head.13529. Epub 2019 Apr 14
[PubMed PMID: 30982963]
[16]
Edvinsson L. Role of CGRP in Migraine. Handbook of experimental pharmacology. 2019:255():121-130. doi: 10.1007/164_2018_201. Epub
[PubMed PMID: 30725283]
[17]
Schwedt TJ, Chong CD. Medication Overuse Headache: Pathophysiological Insights from Structural and Functional Brain MRI Research. Headache. 2017 Jul:57(7):1173-1178. doi: 10.1111/head.13037. Epub 2017 Feb 3
[PubMed PMID: 28160280]
[18]
Lai TH, Wang SJ. Neuroimaging Findings in Patients with Medication Overuse Headache. Current pain and headache reports. 2018 Jan 16:22(1):1. doi: 10.1007/s11916-018-0661-0. Epub 2018 Jan 16
[PubMed PMID: 29340793]
[19]
Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache. 2000 May:40(5):343-50
[PubMed PMID: 10849027]
[20]
Di Lorenzo C, Coppola G, Currà A, Grieco G, Santorelli FM, Lepre C, Porretta E, Pascale E, Pierelli F. Cortical response to somatosensory stimulation in medication overuse headache patients is influenced by angiotensin converting enzyme (ACE) I/D genetic polymorphism. Cephalalgia : an international journal of headache. 2012 Dec:32(16):1189-97. doi: 10.1177/0333102412461890. Epub 2012 Oct 10
[PubMed PMID: 23053304]
[21]
Wei DY, Yuan Ong JJ, Goadsby PJ. Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis. Annals of Indian Academy of Neurology. 2018 Apr:21(Suppl 1):S3-S8. doi: 10.4103/aian.AIAN_349_17. Epub
[PubMed PMID: 29720812]
[22]
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia : an international journal of headache. 2013 Jul:33(9):629-808. doi: 10.1177/0333102413485658. Epub
[PubMed PMID: 23771276]
[23]
Micieli A, Robblee J. Medication-overuse headache. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2018 Mar 12:190(10):E296. doi: 10.1503/cmaj.171101. Epub
[PubMed PMID: 29530871]
[24]
Lee VME, Ang LL, Soon DTL, Ong JJY, Loh VWK. The adult patient with headache. Singapore medical journal. 2018 Aug:59(8):399-406. doi: 10.11622/smedj.2018094. Epub
[PubMed PMID: 30175370]
[25]
Loder E, Weizenbaum E, Frishberg B, Silberstein S, American Headache Society Choosing Wisely Task Force. Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question. Headache. 2013 Nov-Dec:53(10):1651-9. doi: 10.1111/head.12233. Epub 2013 Oct 29
[PubMed PMID: 24266337]
[26]
Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, Geppetti P, Grazzi L, Leone M, Martelletti P, Pini LA, Prudenzano MP, Sarchielli P, Tedeschi G, Russo A, Italian chronic migraine group. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. The journal of headache and pain. 2019 Aug 30:20(1):92. doi: 10.1186/s10194-019-1038-4. Epub 2019 Aug 30
[PubMed PMID: 31470791]
Level 3 (low-level) evidence
[27]
Whalen J, Yao S, Leder A. A Short Review of the Treatment of Headaches Using Osteopathic Manipulative Treatment. Current pain and headache reports. 2018 Oct 5:22(12):82. doi: 10.1007/s11916-018-0736-y. Epub 2018 Oct 5
[PubMed PMID: 30291550]
[28]
Vyas DB, Ho AL, Dadey DY, Pendharkar AV, Sussman ES, Cowan R, Halpern CH. Deep Brain Stimulation for Chronic Cluster Headache: A Review. Neuromodulation : journal of the International Neuromodulation Society. 2019 Jun:22(4):388-397. doi: 10.1111/ner.12869. Epub 2018 Oct 10
[PubMed PMID: 30303584]
[30]
Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for tension-type headache. The Cochrane database of systematic reviews. 2009 Jan 21:(1):CD007587. doi: 10.1002/14651858.CD007587. Epub 2009 Jan 21
[PubMed PMID: 19160338]
Level 1 (high-level) evidence
[31]
Boes CJ, Black DF, Dodick DW. Pathophysiology and management of transformed migraine and medication overuse headache. Seminars in neurology. 2006 Apr:26(2):232-41
[PubMed PMID: 16628534]
[32]
Tassorelli C, Jensen R, Allena M, De Icco R, Sances G, Katsarava Z, Lainez M, Leston J, Fadic R, Spadafora S, Pagani M, Nappi G, the COMOESTAS Consortium. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia : an international journal of headache. 2014 Aug:34(9):645-655
[PubMed PMID: 24558185]
Level 3 (low-level) evidence
[33]
Baraldi C, Pellesi L, Guerzoni S, Cainazzo MM, Pini LA. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. The journal of headache and pain. 2017 Dec:18(1):71. doi: 10.1186/s10194-017-0777-3. Epub 2017 Jul 20
[PubMed PMID: 28730562]
[34]
Biglione B, Gitin A, Gorelick PB, Hennekens C. Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers. The American journal of medicine. 2020 Apr:133(4):412-416. doi: 10.1016/j.amjmed.2019.10.023. Epub 2019 Nov 9
[PubMed PMID: 31712099]
[35]
Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2020 Jan:60(1):58-70. doi: 10.1111/head.13663. Epub 2019 Oct 24
[PubMed PMID: 31647577]
Level 1 (high-level) evidence
[36]
Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA. Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. The Cochrane database of systematic reviews. 2016 Dec 27:12(12):CD012227. doi: 10.1002/14651858.CD012227.pub2. Epub 2016 Dec 27
[PubMed PMID: 28027389]
Level 1 (high-level) evidence
[37]
Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. The Cochrane database of systematic reviews. 2014 May 28:2014(5):CD009108. doi: 10.1002/14651858.CD009108.pub2. Epub 2014 May 28
[PubMed PMID: 24865446]
Level 3 (low-level) evidence
[38]
Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. The Cochrane database of systematic reviews. 2012 Feb 15:2012(2):CD009663. doi: 10.1002/14651858.CD009663. Epub 2012 Feb 15
[PubMed PMID: 22336867]
Level 1 (high-level) evidence
[39]
Havanka H, Dahlöf C, Pop PH, Diener HC, Winter P, Whitehouse H, Hassani H. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clinical therapeutics. 2000 Aug:22(8):970-80
[PubMed PMID: 10972633]
[40]
Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997 Nov:49(5):1210-8
[PubMed PMID: 9371896]
Level 1 (high-level) evidence
[41]
Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia : an international journal of headache. 2008 Apr:28(4):383-91. doi: 10.1111/j.1468-2982.2008.01546.x. Epub 2008 Feb 20
[PubMed PMID: 18294251]
Level 1 (high-level) evidence
[42]
Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. The Cochrane database of systematic reviews. 2001:(3):CD003224
[PubMed PMID: 11687056]
Level 1 (high-level) evidence
[43]
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012 Feb:52(2):292-306. doi: 10.1111/j.1526-4610.2011.02070.x. Epub
[PubMed PMID: 22309235]
[44]
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet (London, England). 2019 Aug 31:394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. Epub 2019 Jul 13
[PubMed PMID: 31311674]
Level 1 (high-level) evidence
[45]
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019 Nov 19:322(19):1887-1898. doi: 10.1001/jama.2019.16711. Epub
[PubMed PMID: 31742631]
Level 1 (high-level) evidence
[46]
Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain : a journal of neurology. 2019 Jul 1:142(7):1894-1904. doi: 10.1093/brain/awz134. Epub
[PubMed PMID: 31132795]
Level 3 (low-level) evidence
[47]
Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(®) ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021 Sep:61(8):1214-1226. doi: 10.1111/head.14184. Epub 2021 Aug 7
[PubMed PMID: 34363701]
[49]
Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2010 Apr 20:182(7):E269-76. doi: 10.1503/cmaj.081657. Epub 2010 Feb 16
[PubMed PMID: 20159899]
[50]
Markley HG. Verapamil and migraine prophylaxis: mechanisms and efficacy. The American journal of medicine. 1991 May 17:90(5A):48S-53S
[PubMed PMID: 2039020]